Francis Crick researchers reveal pathways linking intestinal inflammation and colitis
Affecting over 500,000 people in the UK, IBD comprises Crohn’s disease and ulcerative colitis
Read Moreby Jen Brogan | Apr 15, 2024 | News | 0
Affecting over 500,000 people in the UK, IBD comprises Crohn’s disease and ulcerative colitis
Read Moreby Jen Brogan | Feb 29, 2024 | News | 0
Approximately 80% of patients taking Remicade from diagnosis had symptoms controlled
Read Moreby Anna Smith | Apr 3, 2019 | News | 0
The company proposes to make it available in both pre-filled syringe and pen options.
Read Moreby Selina McKee | Aug 20, 2018 | News | 0
Cost regulators for the NHS in England and Wales have not approved funding for TiGenix and Takeda’s Alofisel – the first allogeneic stem cell therapy to be approved for use across the European Union – for use in Crohn’s patients in draft guidelines.
Read Moreby Selina McKee | Feb 8, 2018 | News | 0
Theravance Biopharma Ireland has signed a global co-development and commercialisation deal with Janssen Biotech focusing on new treatments for inflammatory intestinal conditions, including ulcerative colitis and Crohn’s disease.
Read Moreby Selina McKee | Oct 31, 2017 | News | 0
Pfizer and Celltrion Healthcare have unveiled new data showing that switching patients with Crohn’s disease from Remicade to biosimilar Inflectra showed comparable efficacy, safety and tolerability over a 24-week period.
Read Moreby Selina McKee | Oct 20, 2017 | News | 0
Celgene is abandoning late-stage testing of its experimental drug mongersen for Crohn’s disease after a Data Monitoring Committee concluded that it would be futile to continue.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479